You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Genzyme encouraged by MS drug

Genzyme, a Cambridge unit of French drug maker Sanofi SA, reported the publication of encouraging results from studies of Lemtrada, its drug candidate for treating multiple sclerosis.

Results were published in the online edition of the medical journal Lancet. Lemtrada is being reviewed by European regulators. At some point, Genzyme plans to seek Food and Drug Administration approval.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week